A person can lose more than half their kidney function without feeling a thing. No pain, no obvious warning, no reason to visit a doctor. That biological silence helps explain how chronic kidney disease has ballooned into one of the largest and least-discussed health crises on the planet, now estimated to affect between 674 million and 843 million people and to kill more than 2 million every year.
The numbers have climbed steeply over the past decade, driven by the same forces reshaping global health: rising rates of diabetes, widespread hypertension, aging populations, and health systems that still treat kidney screening as an afterthought. As of June 2026, no single country has fully closed the gap between the scale of the disease and the resources devoted to catching it early.
The scale of the problem
The most widely cited recent estimate comes from a 2023 commentary in Nephrology Dialysis and Transplantation by researchers affiliated with the European Renal Association, the International Society of Nephrology, and the American Society of Nephrology. That analysis placed the number of people living with CKD at approximately 843 million, a figure the authors argued had been “systematically underestimated” by earlier models. Their work drew on updated iterations of the Global Burden of Disease project and additional regional data sources.
A separate consensus report from the KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference, published in Kidney International, put the count at more than 800 million and emphasized that more than 2 million deaths per year are attributable to the disease. The report called CKD “one of the most neglected chronic diseases” and stressed that the majority of those deaths are preventable through earlier detection and better management of blood pressure and blood sugar.
For comparison, the Global Burden of Disease Study 2017 recorded 697.5 million cases of all-stage CKD worldwide, representing a global prevalence of 9.1 percent. The World Health Organization, drawing on GBD 2021 modeling, lists an estimated 674 million on its CKD fact sheet. The jump from roughly 700 million to more than 800 million over several years reflects both a genuine increase in case counts and refinements in how researchers model prevalence across regions with limited surveillance.
In the United States, the Centers for Disease Control and Prevention estimates that about 14 percent of adults have CKD. The U.S. Renal Data System’s 2023 Annual Data Report documented continued increases in end-stage kidney disease incidence and persistent gaps in treatment access by race and geography, even as cardiovascular outcomes have improved for other chronic conditions. Most Americans with early-stage CKD do not know they have it, because the disease produces no symptoms until significant damage has already occurred.
Why the numbers diverge
The gap between 674 million and 843 million is wide enough to matter for policy, but it does not signal a scientific disagreement so much as a measurement challenge. Each estimate uses a different baseline year, a slightly different definition of CKD staging, and a different statistical method for extrapolating from population samples to global totals. The WHO figure relies on a more conservative modeling approach; the ERA/ISN/ASN estimate incorporates broader staging criteria and more recent data.
What every major source agrees on is the direction: CKD prevalence is rising, and it is rising fastest in low- and middle-income countries where diabetes and hypertension are expanding but screening infrastructure is thin. Many of these countries lack national kidney registries or routine laboratory reporting systems that could capture early-stage disease. The result is that global estimates still depend heavily on modeled projections rather than direct patient-level data from the regions where the burden is growing most quickly.
There is also a counting problem at the other end of the disease. CKD dramatically amplifies the risk of heart attacks, strokes, and heart failure. Many patients with advanced kidney dysfunction ultimately die from cardiovascular events, and their death certificates often list the cardiac cause rather than the underlying kidney disease. Different approaches to attributing those deaths can shift estimates of CKD-related mortality by hundreds of thousands.
What early detection actually looks like
The frustrating reality of CKD is that the tools to catch it early are neither expensive nor complicated. A serum creatinine blood test, used to estimate glomerular filtration rate, and a urine albumin test to detect protein leakage can flag kidney trouble years before function collapses. Both can be run during a routine primary care visit and cost only a few dollars in most health systems.
The problem is that these tests are not routinely ordered for the people most at risk. Consensus guidelines from major nephrology societies recommend screening for adults with diabetes, long-standing high blood pressure, cardiovascular disease, or a family history of kidney failure. In practice, screening rates remain low even in wealthy countries. In resource-limited settings, many primary care clinics lack the laboratory capacity to run the tests at all.
When CKD is caught early, the interventions that slow its progression are well established. Blood pressure control and improved blood sugar management remain the foundation. In recent years, SGLT2 inhibitors, a class of drugs originally developed for diabetes, have shown significant kidney-protective effects in large clinical trials, including in patients without diabetes. The mineralocorticoid receptor antagonist finerenone has also demonstrated benefits for patients with diabetic kidney disease. But these treatments work best when started before irreversible scarring has set in, which circles back to the detection gap.
Where policy is falling short
Public health strategies for CKD generally rest on three pillars: preventing the underlying risk factors, building systematic early detection into existing health programs, and ensuring equitable access to treatment for those who progress. On prevention, population-level measures that reduce salt intake, improve access to healthier food, and support tobacco cessation can lower CKD risk indirectly by improving cardiovascular health. On detection, the most pragmatic approach for stretched health systems is to integrate kidney checks into programs that already exist for diabetes and hypertension, rather than building standalone screening campaigns.
Yet even these relatively straightforward steps have been slow to materialize. The KDIGO report noted that most health systems still lack routine detection programs capable of identifying CKD before irreversible damage occurs. Early referral to nephrology, where available, is associated with better preparation for potential kidney replacement therapy and more timely access to transplant. But in many countries, nephrologists are concentrated in urban centers, leaving rural populations with little specialist access.
Closing the data gap
Several recent efforts aim to sharpen the global picture. An analysis of international registry information published in Nephrology Dialysis and Transplantation argued that harmonized reporting standards and expanded surveillance could reduce reliance on modeled projections. Complementary work using population-based cohort data has shown how differences in measurement techniques and case definitions drive apparent discrepancies between studies.
Better data alone will not solve the problem, but it would give governments a clearer basis for allocating resources. Right now, the range between 674 million and 843 million is wide enough to complicate planning for everything from dialysis capacity to drug procurement. Narrowing that range, especially by improving direct surveillance in the countries where CKD is growing fastest, would make it harder for policymakers to treat kidney disease as a secondary concern.
The core message from every major analysis published in recent years is the same: chronic kidney disease is common, it is getting more common, and the window for intervening before patients reach kidney failure is being missed on a massive scale. The disease may be silent, but the evidence is not.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
